leadf
logo-loader
viewHumanigen, Inc.

Humanigen taps drug development expert Edward Jordan for chief commercial officer role ahead of lenzilumab launch

Jordan has more than two decades of commercial operations experience at biotechnology and pharmaceutical companies and has launched more than a dozen products over his career

Boardroom with three people
Jordan worked as senior vice president of biopharma company DBV Technologies, where he built up the company’s commercial organization in preparation for the launch of a pediatric biologic

Humanigen Inc (OTCPINK:HGEN) has named pharmaceutical veteran Edward Jordan its new chief commercial officer, the company announced Monday.

Jordan has more than two decades of commercial operations experience at biotechnology and pharmaceutical companies and has launched more than a dozen products over his career.

He most recently worked as senior vice president of the biopharma company DBV Technologies, where he built up the company’s commercial organization in preparation for the launch of a pediatric biologic. Before that, Jordan held executive roles at AMAG Pharmaceuticals and Teva Pharmaceuticals. 

READ: Humanigen gets regulatory nod to begin Phase 3 coronavirus trial of lenzilumab in Brazil

Jordan’s experience is particularly relevant as Humanigen prepares to launch its coronavirus (COVID-19) drug, lenzilumab.

“We have been actively planning for launch as we develop our lead drug candidate, lenzilumab, for COVID-19,” Humanigen CEO Cameron Durant said in a statement. “Ed’s long tenure in senior commercial leadership roles, coupled with his track record of building cross-functional teams to achieve significant objectives in highly competitive markets, make him ideally suited to further strengthen Humanigen’s commercialization plans.” 

For Jordan, the work of bringing a coronavirus drug to market is personal.

“I’m thrilled to join the Humanigen team at such a pivotal point as we work to bring lenzilumab to market during these difficult and unprecedented times,” he said. "Having recently lost my father to a COVID-19 related condition, overseeing the potential commercialization of lenzilumab has special meaning to me and I’m steadfast in my commitment to get lenzilumab into the hands of professionals for the treatment of COVID-19 and other life-threatening conditions.”

Lenzilumab is designed to treat the cytokine storm, an overactive immune system response to the coronavirus that can cause fever and inflammation and potentially lead to organ failure.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Humanigen, Inc.

Price: - -

OTCMKTS:HGEN
Market: OTCQB
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Humanigen announces 71.8 million dollars in financing

Humanigen (OTCQB: HGEN) Chairman and CEO Cameron Durant joined Steve Darling from Proactive Vancouver with news the company has secured almost 72 million dollars in financing. Durant discusses those making up that financing which is a big part of the story..

on 3/6/20

2 min read